VR Logo

Xilio Therapeutics Inc. (XLO) download report


Healthcare | Biotechnology & Pharma Research

Xilio Therapeutics Inc. (XLO) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients.

IPO Date: 22-Oct-2021

Pres, CEO & Director: Dr. Rene Russo BCPS, Pharm.D, Pharm.D.

Chief Financial Officer: Mr. Salvatore Giovine

Listing: NASDAQ: XLO

Country: United States

Headquarters: Waltham, MA

Website: https://www.xiliotx.com

Key Facts

Market cap: $69.50 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-80.49 Mln

Cash: $176.96 Mln

Total Debt: $20.40 Mln

Insider's Holding: 7.54%

Liquidity: Low

52 Week range: $2.04 - 27.95

Shares outstanding: 27,471,600

Stock Performance

Time Period Xilio Therapeutics (XLO) S&P BSE Sensex S&P Small-Cap 600
YTD-82.00-9.18-18.78
1 month-11.11-4.78-8.00
3 months-59.26-9.66-13.65
1 Year--0.81-17.19
3 Years--10.336.10
5 Years--11.345.87
10 Years--11.749.84
As on 01-Jul-2022